Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF)

Life Sciences

Volumn 81, Issue 3, 2007, Pages 210-217

  Ferreira, M A N D ^a   Barcelos, L S ^a   Teixeira, M M ^a   Bakhle, Y S ^b   Andrade, S P ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Angiogenesis; Chemokines; Cytokines; PAFR KO mice; Tumor

Indexed keywords

CXCL2 CHEMOKINE; HEMOGLOBIN; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CONTROLLED STUDY; EHRLICH ASCITES TUMOR; GENE DELETION; INFLAMMATION; MACROPHAGE; MOUSE; MOUSE STRAIN; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM; SOLID TUMOR; TUMOR GROWTH;

ACETYLGLUCOSAMINIDASE; ANIMALS; ASCITES; CARCINOMA, EHRLICH TUMOR; CHEMOKINE CCL2; CHEMOKINES, CXC; INFLAMMATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL CAVITY; PEROXIDASE; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 34250863814     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.05.003     Document Type: Article

References (39)

1. Andrade S.P., Vieira L.B.G.B., Bakhle Y.S., and Piper P.J. Effects of platelet activating factor (PAF) and other vasoconstrictors on a model of angiogenesis in the mouse. International Journal of Experimental Pathology 73 (1992) 503-513
2. Axelrad T.W., Deo D.D., Ottino P., Van Kirk J., Bazan N.G., and Hunt J.D. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB Journal 18 (2004) 568-570
3. Bailey P.J. Sponge implants as models. Methods in Enzymology 162 (1988) 327-334
4. Baldi E., Bonaccorsi L., Finetti G., Luconi M., Muratori M., Susini T., Forti G., Serio M., and Maggi M. Platelet-activating factor in human endometrium. The Journal of Steroid Biochemistry and Molecular Biology 49 (1994) 359-363
5. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
6. Belo A.V., Barcelos L.S., Ferreira M.A.N.D., Teixeira M.M., and Andrade S.P. Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice. Life Sciences 74 (2004) 2827-2837
7. Berdel W.E., Kulimova E., Kolkmeyer A., Zuhlsdorf M., Serve H., Buchner T., and Oelmann E. Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells. Annals of Hematology 84 (2005) 771-773
8. Bingle L., Lewis C.E., Corke K.P., Reed M.W., and Brown N.J. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. British Journal of Cancer 94 (2006) 101-107
9. Bussolati B., Biancone L., Cassoni P., Russo S., Rola-Pleszczynski M., Montrucchio G., and Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. American Journal of Pathology 157 (2000) 1713-1715
10. Cross A.S., Sakarya S., and Rifat S. Recruitment of murine neutrophils in vivo through endogenous sialidase activity. The Journal of Biological Chemistry 278 (2003) 4112-4120
11. de Castro Junior G., Puglisi F., de Azambuja E., El Saghir N.S., and Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Critical Reviews in Oncology/Hematology 59 (2006) 40-50
12. Denizot Y., Chianea T., Labrousse F., Truffinet V., Delage M., and Mathonnet M. Platelet-activating factor and human thyroid cancer. European Journal of Endocrinology 153 (2005) 31-40
13. Denizot Y., Gainant A., Guglielmi L., Bouvier S., Cubertafond P., and Mathonnet M. Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients. Oncogene 22 (2003) 7222-7224
14. Deo D.D., Axelrad T.W., Robert E.G., Marcheselli V., Bazan N.G., and Hunt J.D. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. The Journal of Biological Chemistry 277 (2002) 21237-21245
15. Fang H.Y., Lin T.S., Lin J.P., Wu Y.C., Chow K.C., and Wang L.S. Cyclooxygenase-2 in human non-small cell lung cancer. European Journal of Surggical Oncology 29 (2003) 171-177
16. Ferreira M.A.N.D., Barcelos L.S., Campos P.P., Vasconcelos A.C., Teixeira M.M., and Andrade S.P. Sponge-induced angiogenesis and inflammation in PAF receptor-deficient mice (PAFR-KO). British Journal Pharmacological 141 (2004) 1185-1192
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Medicine 1 (1995) 27-31
18. Hong K.H., Ryu J., and Han K.H. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105 (2005) 1405-1407
19. Ishii S., and Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Progress in Lipid Research 39 (2000) 41-82
20. Ishii S., Kuwaki T., and Nagase T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. The Journalof Experimental Medicine 187 (1998) 1779-1788
21. Jackson L., and Evers B.M. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treatment and Research 30 (2006) 39-45
22. Jackson J.R., Bolognese B., Mangar C.A., Hubbard W.C., Marshall L.A., and Winkler J.D. The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis. Biochimica et Biophysica Acta 1392 (1998) 145-152
23. Kisker O., Onizuka S., and Banyard J. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Research 61 (2002) 7298-7304
24. Laurenzana A., Cellai C., Vannucchi A.M., Pancrazzi A., Romanelli M.N., and Paoletti F. WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential. Leukemia 193 (2005) 90-95
25. Lee D., and Heymach J.V. Emerging antiangiogenic agents in lung cancer. Clinical Lung Cancer 7 (2006) 304-308
26. Lemieux C., Maliba R., Favier J., Theoret J.F., Merhi Y., and Sirois M.G. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 105 (2005) 1523-1530
27. Lyseng-Williamson K.A., and Robinson D.M. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 20 (2006) 193-195
28. Marrache A.M., Gobeil F., Zhu T., and Chemtob S. Intracellular signaling of lipid mediators via cognate nuclear G protein-coupled receptors. Endothelium: Journal of Endothelial Cell Research 12 (2005) 63-72
29. Montrucchio G., Lupia E., and Battaglia E. Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arteriosclerosis, Thrombosis, and Vascular Biology 20 (2000) 80-88
30. Pease J.E., and Williams T.J. The attraction of chemokines as a target for specific anti-inflammatory therapy. British Journal Pharmacology 147 1 (2006) S212-S221
31. Pitton C., Lanson M., Besson P., Fetissoff F., Lansac J., Benveniste J., and Bougnoux P. Presence of PAF-acether in human breast carcinoma: relation to axillary lymph node metastasis. Journal of the National Cancer Institute 81 (1989) 1298-1302
32. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., and Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
33. Seo K.H., Lee H.S., Jung B., Ko H.M., Choi J.H., Park S.J., Choi I.H., Lee H.K., and Im S.Y. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Research 64 (2004) 6482-6488
34. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European Journal of Cancer 42 (2006) 717-727
35. Teixeira A.S., Araújo F.A., Ferreira M.A.N.D., Barcelos L.S., Teixeira M.M., and Andrade S.P. Angiogenesis and inflammation in skeletal muscle in response to ascites tumor in mice. Life Sciences 78 (2006) 1637-1645
36. Wang L.S., Chow K.C., and Wu Y.C. Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells. Scandinavian Journal of Gastroenterology 37 (2002) 467-475
37. Yano S., Matsumori Y., Ikuta K., Ogino H., Doljinsuren T., and Sone S. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. International Journal of Clinical Oncology 11 (2006) 73-81
38. Zhong H., and Bowen J.P. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Current Medicinal Chemistry 13 (2006) 849-862
39. Zimmerman G.A., McIntyre T.M., Prescott S.M., and Stafforini D.M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Critical Care Medicine 30 5 (2002) S294-S301